GLP-1s, Ohio, and the Cost of Waiting: What This Policy Shift Really Means for You

Written By Christopher Yeoman

In ancient Norse tradition, they’d call this a thing, a gathering of minds leading us today to discuss.

On July 1, 2025, the State of Ohio will eliminate GLP-1 coverage for weight loss in state employee health plans. The official reason? A ballooning Medicaid bill—up from $172 million in 2021 to over $431 million in 2024 (Reuters). But let’s not confuse cause with cover story.

This isn’t about savings. It’s about slowing you down until the market catches up.

⏳ The Pause That Profits

Pharma didn’t fail. It succeeded too fast.

GLP-1s like Ozempic and Wegovy weren’t just popular—they were revolutionary. They disrupted treatment timelines, upended chronic disease management, and exposed how unprepared insurers, supply chains, and support industries really were. From gym culture to supplement stacks, no one was ready.

So the system does what it does best: delay access to consolidate control.

🧪 What’s Really in the Pipeline?

Ohio is pulling back, but Big Pharma is accelerating. Why? Because the next wave of GLP-1 treatments is already lining up:

  • CagriSema – Semaglutide + amylin | ~23% weight loss | Phase III, 2027 (Barron’s)

  • Amycretin – Oral GLP-1 + amylin | ~24% weight loss | In development (FT)

  • Orforglipron – Oral GLP-1 from Eli Lilly | Late 2025 filing (Wired)

  • Triple Agonists – Multi-hormone therapies for higher efficacy | Through 2026+ (Reuters)

These aren’t band-aids. They’re business models—designed to maintain pricing power, expand market reach, and extend patent life through 2032 and beyond.

🏛️ The Real Logic: Profit Protection, Not Cost Containment

Make no mistake—Ohio’s rollback isn’t a rejection of GLP-1s. It’s a safeguard. By pausing coverage, the state avoids premature market saturation while keeping chronic disease revenue streams intact.

  • Fewer GLP-1 prescriptions = More diabetes care

  • Slower weight loss = More bariatric surgeries

  • More time = More monetization runway

That’s balance sheet logic. But for the individual trying to lose weight, improve mobility, or regain health—it’s betrayal.

❌ The Cost of Denial

Removing access to GLP-1s doesn’t just restrict treatment—it amplifies inequality:

  • Those seeking better health lose access.

  • Chronic disease treatments remain covered.

  • The result? Incentivize illness, not prevention.

And whether intended or not, the message is clear:
Weight loss is a luxury, not a right—unless it’s profitable.

🛠️ So What Do You Do Now?

If you’ve lost GLP-1 access—or chose not to rely on it—you’re not out of options.
You’re just out of insurance support.

Here’s where to fight back:

  • Lift weights to retain muscle mass (JAMA).

  • Use protein tactically: Fairlife, IsoPure, Quest—tools that preserve lean mass (Obesity Reviews).

  • Train with intent—not for calorie burn, but for metabolic control.

  • Build community that isn’t built on a script pad.

🧭 Where MyoBio Stands

We don’t care how you got here—GLP-1, keto, stress, surgery, or all of the above.
We care how you hold the line while the industry plays catch-up.

MyoBio trains for sustainability—for muscle, for mood, for real metabolic health.

Because let’s be blunt:
They’re keeping you fat until it’s more profitable not to.

✅ Ready to Push Back?

Christopher Yeoman
Next

Fitness, Capitalism, and the Privilege Divide: A Delicate Balance